We searched Medline and online publications on COPD and tobacco use worldwide (eg, WHO) using the terms COPD, emphysema, tobacco use, epidemiology, cause, emphysema, comorbidities, lung cancer, treatment, pulmonary rehabilitation, physical activity, and exacerbation. We focused on recent publications in English up to 2016 that might be of interest for a general readership.
SeminarChronic obstructive pulmonary disease
Introduction
Chronic obstructive pulmonary disease (COPD) is common worldwide and causes a major health-care burden. Although COPD generally manifests at an older age as part of multimorbidity, there is increasing evidence that events early in life contribute to impaired lung function in adults,1 which suggests that risk factors other than those already known (inhaled particles and gases from cigarette smoking and biomass fuel) are important in the disease's aetiology.
The term COPD might be too general, since the airway abnormalities of chronic bronchitis and the peripheral loss of parenchymal lung texture in emphysema are probably caused by diverse cellular and pathophysiological changes with distinct genetic backgrounds. Advances in lung imaging enable a more detailed view of airway and lung parenchyma abnormalities and novel endoscopic interventions play an increasing role in the management of advanced emphysema. No drug treatment specifically targets emphysema except for the augmentation of α1 antitrypsin in patients with emphysema associated with α1 antitrypsin deficiency.2 Although the results of large clinical trials support a shift from anti-inflammatory treatment with inhaled corticosteroids towards dual bronchodilator treatment for airway pathology,3 further prospective studies will help to clarify the role of inhaled corticosteroid treatment in combination with dual bronchodilator therapy in the prevention of exacerbations.4 By contrast with asthma, there is little hope that COPD-specific biological therapies can be developed.
Section snippets
Epidemiology and causes
The global prevalence of COPD is difficult to estimate because of the different approaches used to calculate prevalence (eg, spirometry-confirmed airflow limitation or surveys).5 The Global Burden of Disease Study 2015 estimated the global prevalence of COPD at about 174 million cases.6 In 2010, Adeloye and colleagues7 estimated a global prevalence of 384 million cases on the basis of spirometric criteria of fixed airflow limitation applied in several epidemiological cohorts. In Canada, the
Pathophysiology
Clinical treatment guidelines issued by global professional societies tend to oversimplify the definition of COPD, which in fact is a heterogeneous and complex disease.24 Furthermore, most (if not all) knowledge about the pathophysiology of the disease is derived from studies of former or current tobacco smokers. However, COPD caused by biomass fuel exposure, for example, might be substantially different from COPD caused by tobacco smoking in terms of phenotype, comorbidities, and progression
COPD and comorbidities
Patients with COPD are often affected by other diseases, such as cardiovascular disease, osteoporosis, muscle weakness, depression, and lung cancer.50, 51, 52 Smoking is a risk factor for comorbidities; others probably include physical inactivity and yet-to-be-identified inflammatory mechanisms (figure 2).50, 51, 53, 54 Several pulmonary mechanisms of inflammation and oxidative stress that damage DNA and result in an imbalance between tissue repair and cell proliferation seem to promote the
Smoking cessation
Smoking cessation is key to reducing progressive decline in lung function over time, as well as exacerbations and smoking-related comorbidities (lung cancer and cardiovascular disease), which decreases mortality in patients with COPD.15, 69, 70 Reducing indoor air pollution by using a stove instead of cooking on an open fire reduces progressive lung function decline in a manner similar to that of smoking cessation.71 Patients with COPD who have a high degree of tobacco dependence, and who have
Conclusions and future directions
Globally, COPD will remain a significant public health problem for the foreseeable future. With risk factors largely unchanged, demographic developments in high-income countries and a significant increase in non-communicable diseases in low-income countries will accelerate this health burden. A better genetic molecular and biological understanding of this disease in its distinct endotypes and phenotypes is needed to enable innovative drug development.
Search strategy and selection criteria
References (141)
Early-life origins of chronic obstructive pulmonary disease
N Engl J Med
(2016)- et al.
Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial
Lancet
(2015) - et al.
Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD
N Engl J Med
(2016) - et al.
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol
Eur Respir J
(2016) GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015
Lancet
(2016)- et al.
Global and regional estimates of COPD prevalence: systematic review and meta-analysis
J Glob Health
(2015) - et al.
Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study
Lancet
(2011) - et al.
Determinants of underdiagnosis of COPD in national and international surveys
Chest
(2015) Chronic respiratory diseases. Burden of COPD
Gender and chronic obstructive pulmonary disease: why it matters
Am J Respir Crit Care Med
Gender differences in COPD: are women more susceptible to smoking effects than men?
Thorax
Incidence of airflow limitation in subjects 65-100 years of age
Eur Respir J
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015
Lancet
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial
Ann Intern Med
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
N Engl J Med
Lung function abnormalities in smokers with ischemic heart disease
Am J Respir Crit Care Med
Global and regional trends in COPD mortality, 1990–2010
Eur Respir J
Global burden of COPD: risk factors, prevalence, and future trends
Lancet
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
Lancet
Global Health Observatory data. Prevalence of tobacco smoking
World Health statistics 2016 data visualizations dashboard. Tobacco control. Region data
Chronic obstructive pulmonary disease in non-smokers
Lancet
An official American Thoracic Society/European Respiratory Society statement: research questions in COPD
Eur Respir Rev
FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure
Am J Respir Crit Care Med
Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease
Proc Am Thorac Soc
Clinical and radiologic disease in smokers with normal spirometry
JAMA Intern Med
Clinical significance of symptoms in smokers with preserved pulmonary function
N Engl J Med
Molecular mechanisms underlying variations in lung function: a systems genetics analysis
Lancet Respir Med
Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank
Lancet Respir Med
Elucidating COPD pathogenesis by large-scale genetic analyses
Lancet Respir Med
Physiological impairment in mild COPD
Respirology
Chronic obstructive pulmonary disease
Lancet
COPD-bronchiectasis overlap syndrome
Eur Respir J
Small-airway obstruction and emphysema in chronic obstructive pulmonary disease
N Engl J Med
Lung-function trajectories leading to chronic obstructive pulmonary disease
N Engl J Med
Asthma transition from childhood into adulthood
Lancet Respir Med
The asthma-COPD overlap syndrome
N Engl J Med
Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Chronic obstructive pulmonary disease: molecular and cellular mechanisms
Eur Respir J
New insights into the immunology of chronic obstructive pulmonary disease
Lancet
Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema
Am J Respir Crit Care Med
Cigarette smoke-induced emphysema: a role for the B cell?
Am J Respir Crit Care Med
New paradigms in the pathogenesis of chronic obstructive pulmonary disease I
Proc Am Thorac Soc
Alveolar cell senescence in patients with pulmonary emphysema
Am J Respir Crit Care Med
Cigarette smoke induces senescence in alveolar epithelial cells
Am J Respir Cell Mol Biol
Accelerated ageing of the lung in COPD: new concepts
Thorax
Pulmonary CT and MRI phenotypes that help explain chronic pulmonary obstruction disease pathophysiology and outcomes
J Magn Reson Imaging
CT-definable subtypes of chronic obstructive pulmonary disease: a statement of the Fleischner Society
Radiology
Systemic manifestations of COPD
Chest
Cited by (713)
Rapid identification of chemical constituents and dynamic metabolic profile of Shenqi-Tiaoshen formula in rat plasma based on UPLC-Q-TOF/MS<sup>E</sup>
2024, Journal of Pharmaceutical and Biomedical AnalysisPulmonary lipofibroblasts in adults and alveolar regeneration in emphysema
2024, Revue des Maladies Respiratoires